Eleanor Kahn, 4, sits with her father, Alex, as nurse Jillian Mercer administers the Moderna vaccine for the coronavirus disease (Covid-19) at Rady Children’s Hospital in San Diego, California, U.S., June 21, 2022, following the CDC’s approval to vaccinate children ages 6 months to 5 years.

Mike Blake | Reuters

Modern The Food and Drug Administration has requested approval of the Omicron booster shot for children, the company announced Friday.

Moderna has filed two separate requests for FDA approval, one for 12- to 17-year-olds and another for 6- to 11-year-olds. – Old, later this year.

The Centers for Disease Control and Prevention said in a document published Tuesday that it expects children to be eligible for Omicron boosters by mid-October, pending FDA approval. CDC’s Immunization Advisory Committee has meetings scheduled for October 19th and 20th.

Pfizer He told a CDC advisory committee earlier this month that he expects to ask the FDA to approve Omicron boosters for children ages 5 to 11 in early October.

American health inspectors Cleared Moderna’s omicron boosters for adults. At the beginning of this month. Pfizer Promotions are approved for persons 12 years of age and older.

The new vaccines target the omicron BA.5 subvariant as well as the original strain of Covid that first emerged in China in late 2019. The FDA and CDC expect the new boosters to provide greater protection against disease and illness because they target the most common microbe. Sub variant.

Older vaccines designed to fight the original strain of Covid are no longer providing meaningful protection against infection and mild illness because the virus has mutated so much. In addition, there is concern that the effectiveness of the first vaccines in preventing hospitalization and serious illness is decreasing.

Public health officials are optimistic about the new omicron BA.5 boosters, although it’s unclear how effective they will be in the real world. The shots were approved without data from human clinical trials

CNBC Health and Science

Read CNBC’s latest global health coverage:

Leave a Reply

Your email address will not be published. Required fields are marked *